von Maltzahn Geoffrey 4
4 · Kaleido Biosciences, Inc. · Filed Mar 4, 2019
Insider Transaction Report
Form 4
von Maltzahn Geoffrey
Director
Transactions
- Conversion
Common Stock
2019-03-04+342,466→ 342,466 total - Conversion
Series A Preferred Stock
2019-03-04−684,932→ 0 total→ Common Stock (342,466 underlying)
Footnotes (1)
- [F1]Each share of Series A Preferred Stock converted into shares of the Issuer's common stock, par value $0.001 ("Common Stock"), on a one-for-two basis upon the closing of the Issuer's initial public offering.